Why test longevity combinations? Single compounds don’t tell the whole story.
The moonshot: SMER28 + Omipalisib. Strong on their own...but what if together they amplify what works and smooth out what doesn’t?
That’s the experiment.
@pumpdotscience
New 2026 🐭 mouse screen: Rapamycin + SMER28 improved performance but caused anemia in some mice — suggesting the combo works, but dosing is critical.
We tested SMER28 + Omipalisib in worms with a low-dose approach. Results soon! @pumpdotscience
https://t.co/6fsx3BcpvO
Longevity doesn’t happen by chance. It happens when we believe in it—and fund it together. 1% of crypto capital could buy us healthier years, fewer diseases, and more moments with the ones we love.
Worth it. 💙
Can we make a potent PI3K/mTOR inhibitor behave like a “precision” longevity drug?
Omipalisib cleanly shuts down PI3K–mTOR, but dialing this pathway down so strongly comes at a cost. PI3K–mTOR sits at the center of metabolism, tissue renewal, and immune function — helping explain common side effects like hyperglycemia, epithelial stress, and immune modulation.
We’re starting in worms, testing a novel combination: SMER28 + Omipalisib.
Could SMER28 let us use lower doses of Omipalisib, push benefits beyond Rapamycin, and teach us something new about how PI3K–mTOR should be modulated for longevity?
And could those lessons translate to humans?